Recently, there has been a growing recognition within the academic community of the importance of immune checkpoint inhibitors (ICI), particularly monoclonal antibodies targeting programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), in treating recurrent/metastatic HNSCC [13]. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.